RSCM
APLS

Rock Springs Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Rock Springs Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-157,900
Closed -$9.98M – 156
2021
Q2 		$9.98M Buy
+157,900
New +$8.15M 0.2% 115

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Rock Springs Capital Management's APLS Position: Q1 2026 in Review

Rock Springs Capital Management increased its Apellis Pharmaceuticals (APLS) stake by 8.1% in Q1 2026, buying an estimated $264K and bringing the position to 162,750 shares worth $6.55M. The position accounts for 0.39% of the portfolio, ranked #59.

Rock Springs Capital Management first reported a position in APLS in Q3 2021 and has held it in 9 quarters since. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Rock Springs Capital Management held 162,750 shares of Apellis Pharmaceuticals worth $6.55M as of Q1 2026.
  • Rock Springs Capital Management bought 12,250 Apellis Pharmaceuticals shares in Q1 2026, an estimated $264K.
  • Apellis Pharmaceuticals made up 0.39% of Rock Springs Capital Management's portfolio in Q1 2026, its #59 holding.
  • Rock Springs Capital Management first reported a position in Apellis Pharmaceuticals in Q3 2021 and has held it in 9 quarters since.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Rock Springs Capital Management's 13F filing for Q1 2026, filed 15 May 2026.